AbbVie (ABBV) Maintains Immunology Dominance as Analysts Downplay Competitive Threat From J&J’s Tremfya to Skyrizi Market Share

AbbVie Inc. (NYSE:ABBV) is 1 of the best stocks for the adjacent decade. On December 12, Morgan Stanley raised the firm’s terms people connected AbbVie to $269 from $261 with an Overweight standing connected the shares.

Earlier connected December 10, HSBC upgraded AbbVie to Buy from Hold with a terms people of $265, which was up from $225. The steadfast highlighted AbbVie’s beardown maturation momentum and accordant operational execution. The steadfast downplayed concerns regarding competitory unit from Tremfya, asserting that it is improbable to airs a important menace to Skyrizi’s marketplace dominance.

In Q3 2025, AbbVie Inc. (NYSE:ABBV) reported full nett revenues of ~$15.8 billion, representing a 9.10% year-over-year rise. This show was driven by the explosive maturation of newer immunology and neuroscience treatments. The institution besides earned $1.86 per share, beating estimates by $0.08. The immunology conception remained the company’s powerhouse, generating $7.9 cardinal successful revenue, an 11.2% increase.

This maturation was fueled by Skyrizi, which saw income leap 46% to $4.7 billion, and Rinvoq, which roseate 34.1% to ~$2.2 billion. These gains efficaciously cushioned the diminution of Humira, which fell 55.7% to $993 cardinal arsenic biosimilar versions continued to erode its marketplace share. Meanwhile, the oncology assemblage remained unchangeable with $1.7 cardinal successful revenue, arsenic the maturation of newer drugs similar Venclexta balanced the interaction of terms negotiations connected Imbruvica.

AbbVie Inc. (NYSE:ABBV) is simply a research-based biopharmaceutical institution that engages successful the probe and development, manufacture, commercialization, and merchantability of medicines and therapies worldwide.

While we admit the imaginable of ABBV arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.